An FDA advisory panel delivered a split but mostly favorable verdict on Grail's Galleri multi-cancer early detection (MCED) blood test, voting 6–4 that it's effective, 7–2 (with one abstention) that its benefits outweigh its risks, and unanimously (10–0) that it's safe. The test analyzes DNA methylation patterns in cell-free blood DNA to flag signals from more than 50 cancer types — including many, like pancreatic and esophageal cancers, that currently have no routine screening option. Grail submitted its premarket approval (PMA) application in January 2026, and the FDA is expected to make a final decision in the coming months.

What swayed many panelists was Galleri's ability to detect cancers that have no existing screening pathway — roughly 70% of U.S. cancer deaths come from cancers with no recommended screening test. But enthusiasm was tempered by the NHS-Galleri trial, which enrolled over 140,000 people and failed to meet its primary endpoint of reducing stage III/IV cancer diagnoses. Sensitivity rates hovered around 31–35%, meaning the test missed roughly two-thirds of cancers diagnosed within 12 months of testing.

By the Numbers:

• 6–4 vote on effectiveness; 7–2 on benefits outweighing risks; 10–0 on safety
• ~35% sensitivity in PATHFINDER 2; ~31.6% in NHS-Galleri
• PPV of 77% (PATHFINDER 2) and 66.2% (NHS-Galleri)
• 53% of MCED-detected cancers in PATHFINDER 2 were stage I or II
• Test costs ~$949; Medicare coverage for FDA-approved MCED tests set to begin in 2028

Why it matters: If the FDA approves Galleri — which it often does when advisors recommend it — it would be the first FDA-approved MCED test, potentially triggering insurance and Medicare coverage and reshaping cancer screening in the U.S. Panelists and experts stress, however, that without mortality data, real-world benefit remains unproven, and misuse of the test as a replacement for — rather than a complement to — standard screenings poses a meaningful risk.